RinuaGene
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
RinuaGene - overview
Established
2021
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Based in Suzhou, China, and founded in 2021, Renjing (Suzhou) Biotechnology Co. , Ltd. , trading as RinuaGene, is an innovative drug developer focused on the research and development of messenger ribonucleic acid (mRNA)-based innovative drugs. Dr.
Yijie Dong, founder of the company, was from Bristol-Myers Squibb Co. The members of the company's core team have worked for multinational companies such as The Liposome Company, Merck, Novartis, Johnson & Johnson, and AstraZeneca. In April 2026, RinuaGene raised CNY 200 million in series A funding. The company conducts research on messenger RNA-based drugs and provides users with clinical research, drug development and GMP production services.
The core pipeline is therapeutic oncology vaccines. RinuaGene also has three technology platforms for linear mRNA, circular mRNA and novel LNP targeted delivery and has developed its own AI algorithm and high-throughput screening platform. The company's revenue is generated by providing innovative drugs. The series A funds raised will be primarily used for the clinical advancement of its core pipeline, commercialization, and the commercialization of its innovative achievements.
Current Investors
Chang'an Capital, K2VC, Changsha Truking Investment Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.rinuagene.com/cn/
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.